A Multi-Center Controlled Study to Characterize the Real-world Outcomes of High Rate Spinal Cord Stimulation Therapy Using Boston Scientific (BSC) PRECISION Spinal Cord Stimulator System
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Pain
- Sponsor
- Boston Scientific Corporation
- Enrollment
- 73
- Locations
- 5
- Primary Endpoint
- Percentage of Low Back Pain Responders
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The primary objective of this study is to characterize the real-world outcomes of spinal cord stimulation (SCS) therapy as an aid in the management of chronic intractable pain of the trunk, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain using the Boston Scientific (BSC) PRECISION Spinal Cord Stimulator System with MultiWave Technology.
Detailed Description
The purpose of this study is to characterize the real-world outcomes of spinal cord stimulation (SCS) therapy as an aid in the management of chronic intractable pain of the trunk, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain using the Boston Scientific (BSC) PRECISION Spinal Cord Stimulator System with MultiWave Technology.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Complaint of persistent or recurrent low back pain for at least 180 days prior to Screening
- •Willing and able to comply with all protocol-required procedures and assessments/evaluations
- •Subject signed a valid, ethics committee (EC)-approved informed consent form (ICF) provided in local language
Exclusion Criteria
- •High surgical risk
- •Previous spinal cord stimulation trial or is already implanted with an active implantable device(s) (e.g. pacemaker, drug pump, implantable pulse generator)
- •A female who is pregnant, is breastfeeding, or is of childbearing potential and planning to get pregnant during the course of the study or not using adequate contraception.
- •Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study
- •Any diagnosis or condition that, in the clinician's best judgment, might confound reporting of study outcomes
Outcomes
Primary Outcomes
Percentage of Low Back Pain Responders
Time Frame: 3 months
Percentage of low back pain responders at 3 months post-activation with no increase in opioids from Baseline to 3 months post-activation